Introduction Ischaemic heart disease (IHD) remains a leading cause of morbidity and mortality worldwide and poses an ...
Lumosa Therapeutics (Lumosa; 6535.TWO) today announced positive results from two independent Phase 2 clinical trials with its novel stroke drug LT3001 (Odatroltide). LT3001 is a first-in-class ...
As stroke systems of care evolve, clinicians are increasingly torn between the known safety of traditional, aggressive ...
Results from the CHOICE-2 trial show a 15% absolute increase in excellent functional outcomes with intra-arterial alteplase ...
MedPage Today on MSN
Neuroprotective agent improved outcomes after acute ischemic stroke
The PSD-95 inhibitor also had a favorable safety profile in phase III trial ...
Chamorro argued that the apparent difference in mortality likely reflects an "extremely low" event rate among control ...
Background International guidelines recommend percutaneous coronary intervention within 120 min for high-risk acute coronary syndrome. In Indonesia, a sprawling archipelago with a rising ...
Tenecteplase failed to outperform aspirin for vision recovery when administered within 4.5 hours of onset of acute central ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results